An Official Website of the United States Government
Preclinical Validation of Human Apyrase in Stroke Models
- Small Business Information
-
Woman-Owned: NoMinority-Owned: NoHUBZone-Owned: No
- Phase 1
-
Fiscal Year: 2007Title: Preclinical Validation of Human Apyrase in Stroke ModelsAgency: HHSContract: 1R43NS060175-01Award Amount: $187,435.00
Abstract:
DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for acute ischemic stroke which is a leading cause of death and disability with almost no effective therapy for most patients. This enzyme strongly inhibits platelet a ctivation and aggregation with modest bleeding risk. Using a protein informatics approach, we have successfully engineered a human apyrase, APT102, which exhibits significantly higher enzymatic activity and platelet inhibition than the wild-type apyrases. Importantly, APT102 conferred cerebroprotection against experimental stroke without inducing intracerebral hemorrhage. With the Phase I grant support, we will develop a process for high-yield purification of APT102. We will then utilize clinically relevant embolic model to validate whether APT102 provides significant neuroprotective effect without increased bleeding risk. Human apyrase represents a highly promising therapy for acute ischemic stroke. We will utilize a clinically relevant embolic model to val idate whether the protein provides significant neuroprotective effect without increased bleeding risk.Small Business Information at Submission:APT THERAPEUTICS, INC.
APT THERAPEUTICS, INC. 893 NORTH WARSON ROAD SAINT LOUIS, MO 63141EIN/Tax ID: 431947715DUNS: N/ANumber of Employees: N/AWoman-Owned: NoMinority-Owned: NoHUBZone-Owned: No
Award Information
|
Agency: Department of Health and Human Services |
Branch: N/A |
Award ID: 85939 |
Program Year/Program: 2007 / SBIR |
|
Agency Tracking Number: NS060175 |
Solicitation Year: N/A |
Solicitation Topic Code: N/A |
Solicitation Number: N/A |